Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
     Ventavis Support
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Ventavis® (iloprost) Support

Comprehensive Services and Support

  • Patient enrollment and referrals to specialty pharmacy distributors
  • Verification of insurance and/or patient assistance programs
  • Training in use of the I-neb AAD System by nurse educators
  • Patient support from registered nurses by phone
  • Patient education and support by e-mail and newsletter

Request a Ventavis representative

There are two ways to request a visit from a Ventavis representative:

1) Use the form below to submit your contact information to Actelion Pharmaceuticals US, Inc. and a representative will contact you by phone or e-mail to arrange an appointment.

     

* Required field
 

Name *

  
 

Specialty *

 
 

Address 1 *

 
 

Address 2  

 
 

City *

 
 

State *

  Zip *
 

Phone *

 
 

E-mail *

 
     

2) If you would like to contact your local Ventavis representative directly, please fill in your name, zip code, and e-mail address below and we will send you his or her contact information.

 

Name *

 
 

Zip *

 
 

E-mail *

 
     

I-neb AAD System User Guide
The I-neb AAD System is a registered trademark of Philips Respironics.


* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION